Launch of Calcium Gluconate Injection USP - Glenmark Pharmaceuticals Ltd

Code BSE: 532296 NSE: $GLENMARK Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, “The launch of Calcium Gluconate Injection USP marks another important step in strengthening Glenmark’s U.S. injectables business and expanding our hospital portfolio. It reflects the disciplined execution of our strategy to build a differentiated and sustainable injectables business – one that addresses institutional needs, supports greater supply resilience and deepens Glenmark’s relevance across the U.S. healthcare system,” he added.